Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
British Columbia Cancer Agency
All men will have a baseline transrectal ultrasound for brachytherapy planning that has demonstrated an enlarged prostate with or without pubic arch obstruction. After signing the informed consent document they will have a loading dose of 240 mg Degarelix and then monthly maintenance dose injections of 80 mg until such time as sufficient prostate reduction has occured (2-3 months) or they complete the 6 months of required androgen ablation for their disease status.
Age
40–80
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Histologic diagnosis of prostate cancer
Favorable risk disease (cT1 or T2a, Gleason score (GS) 6, and Prostate Specific Antigen (PSA) \< 10 ng/mL)
Low-tier intermediate risk disease (cT2c,GS=6,and PSA 10-15 ng/mL, OR GS=7 and PSA \< 10 ng/mL)
Intermediate risk disease AND androgen deprivation therapy recommended by the treating physician for oncologic reasons such as (≥ 50% positive biopsy cores,cT2c,PSA 15-20 ng/mL,GS=7)
Patient requires baseline planning trans-rectal ultrasound for the purposes of prostate brachytherapy, showing prostate volume \> 40 mL and pubic arch interference (not required for those requiring androgen ablation for oncologic reasons)
You may not be if
castrate serum testosterone level
previous or concurrent pelvic radiotherapy
unable to give written informed consent
contraindications to permanent seed prostate brachytherapy or to androgen deprivation therapy
prior treatment for prostate cancer
prior trans-urethral resection of the prostate
previous therapy with a 5-α reductase inhibitor, anti-androgen agent, or LHRH agonist
previous therapy with degarelix
Clareo Health | Feasibility and Toxicity of Degarelix for Prostate Downsizing Prior to Permanent Seed Prostate Brachytherapy
